Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane.
Scher H, Jendrisak A, Gill A, Barnett E, Gopalan A, Zaidi S, Benoliel H, Carbone E, Byun J, Schonhoft J, Wenstrup R. Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane. Journal Of Clinical Oncology 2020, 38: 5572-5572. DOI: 10.1200/jco.2020.38.15_suppl.5572.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen receptor signaling axisCirculating tumor cellsPatients treated with platinumSmall-cell lung cancerCTC subtypesCastration-resistant prostate cancerCirculating tumor cells subtypesSmall-cell histologyPlatinum-based therapyAR protein expressionSmall-cell carcinomaAnalysis of circulating tumor cellsSmall-cell morphologyAnalytically validated assaysAssess drug activityLife-prolonging drugsCK+ cellsSmall cell/neuroendocrineTherapy linesOn-therapyProstate cancerPharmacodynamic changesTreated patientsTumor cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply